AFFILIATIONS
1 Institute of Clinical Pharmacology, LMU University Hospital, LMU Medizin, LMU Munich, Munich, Germany
2 Institute of Clinical Pharmacology, LMU University Hospital, LMU Medizin, LMU Munich, Munich, Germany
3 Institute of Clinical Pharmacology, LMU University Hospital, LMU Medizin, LMU Munich, Munich, Germany
4 Department of Medicine III, LMU University Hospital, LMU Medizin, LMU Munich, Munich, Germany, Laboratory for Translational Cancer Immunology, LMU Gene Center, LMU Munich, Munich, Germany
5 Institute of Clinical Pharmacology, LMU University Hospital, LMU Medizin, LMU Munich, Munich, Germany
6 Roche Innovation Center Zurich, Roche Pharma Research & Early Development, Schlieren, Switzerland
7 Bavarian Cancer Research Center (BZKF), Munich, Germany, Department of Medicine III, LMU University Hospital, LMU Medizin, LMU Munich, Munich, Germany, German Cancer Consortium (DKTK), Partner Site Munich, a partnership between the DKFZ Heidelberg and the LMU University Hospital, Munich, Germany, Institute of Clinical Pharmacology, LMU University Hospital, LMU Medizin, LMU Munich, Munich, Germany
8 Department of Medicine III, LMU University Hospital, LMU Medizin, LMU Munich, Munich, Germany, Laboratory for Translational Cancer Immunology, LMU Gene Center, LMU Munich, Munich, Germany
9 Institute of Clinical Pharmacology, LMU University Hospital, LMU Medizin, LMU Munich, Munich, Germany
10 Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany
11 Institute of Clinical Pharmacology, LMU University Hospital, LMU Medizin, LMU Munich, Munich, Germany
12 Institute of Clinical Pharmacology, LMU University Hospital, LMU Medizin, LMU Munich, Munich, Germany
13 Institute of Clinical Pharmacology, LMU University Hospital, LMU Medizin, LMU Munich, Munich, Germany
14 Institute of Clinical Pharmacology, LMU University Hospital, LMU Medizin, LMU Munich, Munich, Germany
15 Institute of Clinical Pharmacology, LMU University Hospital, LMU Medizin, LMU Munich, Munich, Germany
16 Institute of Clinical Pharmacology, LMU University Hospital, LMU Medizin, LMU Munich, Munich, Germany
17 Roche Innovation Center Zurich, Roche Pharma Research & Early Development, Schlieren, Switzerland
18 Einheit für Klinische Pharmakologie (EKLiP), Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU), Neuherberg, Germany, German Cancer Consortium (DKTK), Partner Site Munich, a partnership between the DKFZ Heidelberg and the LMU University Hospital, Munich, Germany, Institute of Clinical Pharmacology, LMU University Hospital, LMU Medizin, LMU Munich, Munich, Germany
19 Department of Medicine III, LMU University Hospital, LMU Medizin, LMU Munich, Munich, Germany, German Cancer Consortium (DKTK), Partner Site Munich, a partnership between the DKFZ Heidelberg and the LMU University Hospital, Munich, Germany
20 Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany
21 Department of Medicine III, LMU University Hospital, LMU Medizin, LMU Munich, Munich, Germany, German Cancer Consortium (DKTK), Partner Site Munich, a partnership between the DKFZ Heidelberg and the LMU University Hospital, Munich, Germany, Laboratory for Translational Cancer Immunology, LMU Gene Center, LMU Munich, Munich, Germany
22 Department of Biochemistry, Faculty of Chemistry and Pharmacy, LMU University, Munich, Germany, Roche Innovation Center Zurich, Roche Pharma Research & Early Development, Schlieren, Switzerland
23 Bavarian Cancer Research Center (BZKF), Munich, Germany, Department of Medicine III, LMU University Hospital, LMU Medizin, LMU Munich, Munich, Germany, German Cancer Consortium (DKTK), Partner Site Munich, a partnership between the DKFZ Heidelberg and the LMU University Hospital, Munich, Germany, Institute of Clinical Pharmacology, LMU University Hospital, LMU Medizin, LMU Munich, Munich, Germany
24 Einheit für Klinische Pharmakologie (EKLiP), Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU), Neuherberg, Germany, German Cancer Consortium (DKTK), Partner Site Munich, a partnership between the DKFZ Heidelberg and the LMU University Hospital, Munich, Germany, Institute of Clinical Pharmacology, LMU University Hospital, LMU Medizin, LMU Munich, Munich, Germany
ABSTRACT
Introduction
Chimeric antigen receptor (CAR) T cell therapy has shown limited efficacy in acute myeloid leukemia (AML) due to the lack of suitable target antigens, antigen heterogeneity, and antigen-negative relapse. Adapter CAR T cells can address these challenges. Anti-P329G adapter CAR T cells recognize the P329G mutation within the Fc region of human IgG1 antibodies carrying P329G L234A/L235A (PGLALA) for Fc silencing. PGLALA-Fc-mutated antibodies have already been clinically validated against multiple tumor antigens and can be readily combined with anti-P329G CAR T cells. Here, we applied anti-P329G adapter CAR T cells for reversible, sequential, and simultaneous targeting of CD33 and CD123 to address antigen heterogeneity and escape in AML.
Methods
ScFv-based second-generation anti-P329G CAR T cells were combined with human PGLALA-Fc-mutated antibodies targeting the AML-associated antigens CD33 (CD33 PG) and CD123 (CD123 PG). Conventional anti-CD33 CAR and anti-CD123 CAR T cells incorporating scFvs derived from the respective PGLALA-Fc-mutated antibody served as positive controls. Untransduced and anti-CD19 CAR T cells were used as negative controls. T cells were derived from healthy donors and AML patients. Target antigen expression and CAR T cell activation, proliferation, cytokine production, and cytotoxicity were assessed in AML cell lines and primary patient samples using flow cytometry-, dSTORM-, ELISA-, luciferase-, and IncuCyte live-cell imaging-based assays. THP-1 CD33-knockout (CD33KO) and CD123-knockout (CD123KO) cell lines were generated to model antigen loss and escape. In vivo efficacy was evaluated in immunodeficient mice bearing THP-1 or MV4-11 tumors and in a heterogeneous AML model comprising a mixture of THP-1 wild-type and THP-1 CD33KO cells.
Results
Expression of CD33 and CD123 on selected AML tumor cell lines and primary patient samples was confirmed by flow cytometry and dSTORM analysis. Anti-P329G CAR T cells were activated specifically and dose-dependently only in presence of the respective antigen in combination with the antigen-recognizing antibody. Anti-P329G CAR T cells combined with the CD33 PG and CD123 PG antibodies mediated robust and antigen-specific in vitro activation, cytokine production, proliferation, and cytotoxicity when co-cultured with different AML cell lines and primary AML blasts. Potent effector functions were observed using T cells derived from both healthy donors and patients with AML.
Adapter antibody removal in vitro reduced subsequent CAR T cell activation, and switching to alternative antigen-specific adapters demonstrated reversible and sequential targeting. Functional knockout of CD33 and CD123 in the generated THP-1 cell lines was confirmed by the absence of killing with the corresponding adapter in luciferase-based cytotoxicity assays. Dual CD33/CD123 targeting with the anti-P329G CAR T cells lead to potent killing in co-cultures with primary AML blasts, paralleled by higher cytokine production than in monospecific targeting conditions. The sequential targeting approach maintained serial killing in the presence of antigen-loss variants in vitro, with sustained killing through seven rounds of tumor-cell rechallenge monitored by Incucyte live-cell imaging. Consistently, IFN-γ production in later rounds was maintained only under modular sequential targeting conditions.
In THP-1 and MV4-11 in vivo xenograft models, anti-P329G CAR T cells combined with the CD33 PG and CD123 PG antibodies lead to superior survival and tumor control compared with control groups. In a mixed THP-1 wild-type/CD33KO in vivo model simulating antigen escape, dual CD33/CD123 targeting achieved superior tumor control compared with monospecific targeting, as demonstrated by reduced BLI signal, prolonged survival, and lower bone marrow tumor burden at the termination time point.
Conclusions
Anti-P329G adapter CAR T cells enable potent, reversible, and combinatorial targeting of CD33 and CD123 in AML. Dual CD33/CD123 targeting improved control of heterogeneous AML and prevented treatment failure caused by antigen escape in complementary in vitro, in vivo and patient-derived models, supporting further translational development of this approach for AML.